First international TNBC conference meeting report

Rida, Padmashree; Ogden, Angela; Ellis, Ian O.; Varga, Zsuzsanna; Wolff, Antonio C.; Traina, Tiffany A.; Hatzis, Christos; Palmer, Julie R.; Ambrosone, Christine B.; Lehmann, Brian D.; Nanda, Rita; Montgomery Rice, Valerie; Brawley, Otis W.; Torres, Mylin A.; Rakha, Emad; Aneja, Ritu

Abstract

Recently, Georgia State University’s Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from Sept. 18 to 20, 2017, in Atlanta, USA. The conference featured a stellar line-up of domestic and international speakers and diverse participants including TNBC survivors, luminaries in breast cancer research, medical students and fellows, clinicians, translational researchers, epidemiologists, biostatisticians, bioinformaticians, and representatives from the industry. This report distills the burning questions that spiked the event and summarizes key themes, findings, unique opportunities and future directions that emerged from this confluence of thought leaders.

Citation

Rida, P., Ogden, A., Ellis, I. O., Varga, Z., Wolff, A. C., Traina, T. A., …Aneja, R. (2018). First international TNBC conference meeting report. Breast Cancer Research and Treatment, 169(3), 407-412. https://doi.org/10.1007/s10549-018-4692-3

• Journal Article Type: Article
• Acceptance Date: Jan 23, 2018
• Online Publication Date: Feb 8, 2018
• Publication Date: 2018-06
• Deposit Date: Oct 24, 2018
• Journal: Breast Cancer Research and Treatment
• Print ISSN: 0167-6806
• Electronic ISSN: 1573-7217
• Publisher: Springer Verlag
• Peer Reviewed: Peer Reviewed
• Volume: 169
• Issue: 3
• Pages: 407-412
• DOI: https://doi.org/10.1007/s10549-018-4692-3
• Keywords: Triple negative breast cancer; Racial disparities; Targeted drugs; Immunotherapy; Molecular subtypes
• Public URL: https://nottingham-repository.worktribe.com/output/1186469
• Publisher URL: https://link.springer.com/article/10.1007%2Fs10549-018-4692-3